Cytogen Corporation has sold its contract manufacturing business to Purdue Pharma


Transaction Type:

Special Situations

Cytogen Corporation – This publicly-traded, Princetonbased biopharmaceutical company retained SC&H Capital to sell its non-performing contract manufacturing division.  In eight weeks, SC&H had negotiated 50% improvements to initial offers from two separate buyers; both of which retained management and employees, resolved lease obligations, and provided favorable agreements to Cytogen for continued manufacturing of its proprietary products. After SC&H negotiated a long-term lease between the buyer and Cytogen’s landlord, a sale to Purdue Pharma was completed. 

Transaction Leaders

Hank Waida


Ken Mann

Managing Director